万泰生物(603392.SH)子公司参与国家免疫规划疫苗集中采购项目入围

Core Viewpoint - The company, Wantai Biological Pharmacy Enterprise Co., Ltd. (万泰生物), announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has participated in the bidding for the 2025 National Immunization Program vaccine centralized procurement project for the bivalent human papillomavirus vaccine, successfully making it onto the procurement list [1] Group 1 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, indicating a significant government initiative in vaccine procurement [1] - If the company signs the procurement contract and organizes production and supply, it will help expand the sales scale of the listed products and increase market share [1] - This development is expected to promote the domestic market expansion of the company's listed products and enhance its brand influence [1]